Aug 19th 2013 - Edison Investment Research today published a report on TopoTarget entitled "Only A Delay". In summary, the report says:
The filing of belinostat with the FDA has been delayed until Q413, following a pre-NDA meeting. No new data are required; however, Topotarget and its partner Spectrum Pharmaceuticals require more time to fine-tune their NDA submission. Given the data that has been reported from the BELIEF trial, including the impressive subgroup data reported in June, we do not believe that the delay should give rise to concern. Despite the delay, we increase our valuation by DKK54m to DKK1,339m due to tight cost control.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »